- Home
- VANI vs MIRM Comparison
VANI vs MIRM Comparison
Compare VANI & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VANI
- MIRM
- Stock Information
- Founded
- VANI 1998
- MIRM 2018
- Country
- VANI United States
- MIRM United States
- Employees
- VANI N/A
- MIRM N/A
- Industry
- VANI Biotechnology: Electromedical & Electrotherapeutic Apparatus
- MIRM Biotechnology: Pharmaceutical Preparations
- Sector
- VANI Health Care
- MIRM Health Care
- Exchange
- VANI Nasdaq
- MIRM Nasdaq
- Market Cap
- VANI 68.1M
- MIRM 2.5B
- IPO Year
- VANI 2014
- MIRM 2019
- Fundamental
- Price
- VANI $1.27
- MIRM $49.09
- Analyst Decision
- VANI Strong Buy
- MIRM Strong Buy
- Analyst Count
- VANI 1
- MIRM 9
- Target Price
- VANI $4.00
- MIRM $66.22
- AVG Volume (30 Days)
- VANI 148.9K
- MIRM 449.1K
- Earning Date
- VANI 08-12-2025
- MIRM 08-06-2025
- Dividend Yield
- VANI N/A
- MIRM N/A
- EPS Growth
- VANI N/A
- MIRM N/A
- EPS
- VANI N/A
- MIRM N/A
- Revenue
- VANI N/A
- MIRM $379,251,000.00
- Revenue This Year
- VANI N/A
- MIRM $35.83
- Revenue Next Year
- VANI N/A
- MIRM $16.83
- P/E Ratio
- VANI N/A
- MIRM N/A
- Revenue Growth
- VANI N/A
- MIRM 69.31
- 52 Week Low
- VANI $0.91
- MIRM $33.45
- 52 Week High
- VANI $1.50
- MIRM $54.23
- Technical
- Relative Strength Index (RSI)
- VANI 61.03
- MIRM 53.95
- Support Level
- VANI $1.13
- MIRM $49.39
- Resistance Level
- VANI $1.33
- MIRM $51.93
- Average True Range (ATR)
- VANI 0.07
- MIRM 1.53
- MACD
- VANI 0.00
- MIRM -0.27
- Stochastic Oscillator
- VANI 63.64
- MIRM 31.40
About VANI Vivani Medical Inc. (DE)
Vivani Medical Inc is a preclinical-stage biopharmaceutical company. The company develops miniaturized, subdermal implants utilizing its proprietary NanoPortal technology to enable long-term, near-constant-rate delivery of a broad range of medicines to treat chronic diseases. It has two reporting segments, the Biopharm Division and the Neuromodulation Division. The Biopharm Division includes activities from NPM and Vivani Medical Australia Pty Ltd, and the Neurostimulation Division includes activities from Cortigent and its subsidiary in Switzerland.
About MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.